Look Who's Attending | Last Chance to Save up to $400

Last Chance to Save up to $400 is This Friday, October 9th
Register Today
Be Sure to use code: D15172BLOG

  

Connect with hundreds of your colleagues this December in San Diego at the largest and most trusted Antibody Engineering & Therapeutics event to discover, engineer and develop novel and next generation antibody modalities across diverse disease indications. Included with your 4-day registration fee this year is a new 2-day Antibody-Drug Conjugate track that will showcase the latest progress and clinical updates from the most exciting ADC programs in development.

Secure your seat today to attend this year's meeting and access:
• 100+ speaker presentations covering critical scientific and development updates that can accelerate your antibody research, discovery efforts and clinical programs - download the agenda. 
• 50+ exhibitors to keep you on the pulse of evolving technologies
• 100+ scientific posters to give you first-hand updates on unpublished, peer-submitted research projects
• 700+ global antibody researchers for you to connect with onsite to forge successful scientific and business partnerships

A sample of the attending companies:
• Abbvie
• Albert Einstein College of Medicine
• Amgen
• Bayer Healthcare
• Biogen
• Boehringer Ingelheim
• Boston College
• Boston University
• Bramhill Biological Consulting
• Bristol Myers Squibb
• Celgene Corporation
• Covagen AG
• Daiichi Sankyo
• Dana Farber Cancer Institute
• Dartmouth College
• David Geffen School of Medicine at UCLA
• Development Center for Biotechnology
• Eli Lilly & Company
• EnGen Bio
• Esbatech A Novartis Company
• Genentech
• Genesun Biopharmaceutical      
• Genmab BV
• Genomics Inst of Novartis Research
• Genzyme Corporation
• Georgetown University
• GlaxoSmithKline
• Global Biological Standards Institute
• Imaginab
• Immunocore
• ImmunoGen
• Janssen
• Johnson & Johnson
• Jounce Therapeutics
• Kookmin University
• KTH Royal Institute of Technology
• Massachusetts Institute of Technology
• Maxcyte Inc
• MD Anderson Cancer Center
• MedImmune
• Meditope Biosciences
• Memorial Sloan Kettering Cancer Center
• Merck
• Merrimack Pharmaceuticals Inc
• National Cancer Center Hospital East
• National Cancer Institute NIH
• National Institute for Communicable Diseases
• National Research Council Canada
• Novartis
• Novo Nordisk   
• OMT Therapeutics
• Oslo University Hospital, Rikshospi
• Oxford University Kellogg College
• Panorama Research Institute
• Pfizer
• Queen Mary University of London
• Regeneron
• Research Corporation Technologies
• Roche
• Royal Institute of Technology (KTH)
• Sanofi
• Seattle Genetics
• Simon Fraser University
• Stanford University Medical Center
• Stanford University School of Medicine
• Taipei Medical University
• Takeda
• Tel Aviv University
• Teva Pharmaceuticals
• The Rockefeller University
• The Scripps Research Institute
• The University Of Tokyo
• Tokyo University of Pharmacy and Life Sciences• UCL Cancer Institute
• UMass Medical School
• Univ. of Texas MD Anderson Cancer Ct
• University of Cincinnati College of Medicine
• University of Pittsburgh Cancer Institute
• Vaccinex
• Yale School of Medicine and more!

Don't miss out! Join the growing list of attendees at the largest antibody engineering and therapeutics event in the industry! This Friday, October 9th is your last chance to take advantage of the early-bird savings of up to $400. Be sure to use code: D15172BLOG – Register here.

Best,
The Antibody & Protein Therapeutics – From Discovery to Production Team
@ibcusa
#AntibodyEng
http://futurebiopharma.blogspot.com/

Share this article with your social network, just click below to share now!

Share |

Might the sun be setting on process-scale chromatography for the purification of biopharmaceuticals?

Browsing through the program for BPI Boston 2015 I was really excited to see Abhinav Shukla is chairing a session in the Recovery & Purification track on novel approaches to non-chromatographic purification. The session will be on Tuesday afternoon starting at 1.25pm.

Like I explained in last week’s blog the subject it’s a subject that is particularly to my heart as it’s the field I worked in as a fresh engineer in my first role upon completing my doctorate.

Bottlenecks in downstream processing

Packed-bed chromatography is, of course, the workhorse of large-scale therapeutic protein purification. The selectivity of chromatography steps especially when operated together as part of an integrated downstream purification train allows very high levels of drug purity to be achieved ensuring patient safety.

The trade-off from a method like this which has such a great ability to resolve different molecular species to give a pure product is that capacity and throughput can be compromised. This was not such an issue during the early days of the industry but as it has developed and bioreactor productivity has increased at a near exponential rate the reliance on chromatography has arguably lead to bottlenecks in purification processes.

The cost of Protein A chromatography

For some within the industry the greatest concern is around Protein A affinity chromagraphy which is an extremely common capture step for monoclonal antibodies once harvested from bioreactors. The extremely high selectivity of Protein A resin means it has a somewhat lower capacity than some alternatives and its high cost of manufacture is reflected in its cost. Though significant advances have been made in Protein A resin technology over the past 20 years there is still significant interest in finding a suitable alternative. The cost of such a consumable means it is imperative biomanufacturers must take care when using and storing the resin to maximize its lifetime.

 Novel methods for therapeutic protein purification

Elastin-like polypeptides (ELP) are fascinating biopolymers that will reversibly transition from soluble molecules to insoluble form at relatively low temperatures. A modest temperature increase will allow an ELP-tagged protein to precipitate out of solution where it can be purified from contaminants using a traditional solid-liquid separation technique such as centrifugation or hollow fibre microfiltration. Resolubilization into a desired solvent or buffer will occur when the temperature of the suspended purified protein is reduced. A great description of the method for purifying ELP-tagged proteins without recourse to chromatography is described in a publication from Ashutosh Chilkoti and others of Duke University.

Author of the 2013 article ‘Emerging Challenges to Protein A’ (BioProcess International. Oct 1, 2013) Pete Gangnon is scheduled to present at the session and hopefully will be sharing more insights into highly innovative antibody purification process he describes in the article. Gangnon highlights two techniques used in combination with one another, firstly chromatin-directed clarification followed by an approach called steric exclusion chromatography which uses polyethylene glycol and hydrophilic particle surfaces. These techniques used with a Capto Adhere chromatography step to complete the purification process gave yields of over 80% while reducing host cell protein levels to <1ppm and aggregate to <0.1%.

What is your experience?

Have you tried non-chromatographic purification methods? How successful was it? Do you think that packed-bed chromatography may have had its day?

Nick Hutchinson

LinkedIn (https://uk.linkedin.com/pub/dr-nick-hutchinson/0/b38/37)

Join me at #BPIconf

Share this article with your social network, just click below to share now!

Share |